SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Hands tearing money over red background. Professional challenges, disagreement, greed. Contemporary art collage. Concept of financial literacy, economic, business, money
Layoffs
Sanofi Cuts Off Antibody Partner, Forcing 80% Headcount Reduction at IGM
After losing its powerhouse partner, IGM Biosciences closed “most” of its labs and offices and initiated a strategic review of potential strategic alternatives and options for the business.
May 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Handshake of man and robot. Modern technologies. Art collage.
Artificial intelligence
Amid Layoffs, Delays, FDA Turns to AI for Speedy Reviews
The FDA expects to fully integrate its AI approach by June 30, though its different centers have been instructed to start the rollout immediately.
May 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Trendy halftone collage. A hand holds a ringing alarm clock. Time, hurry up. Vector business concepts for graphic and web design, marketing and print materials, social media. Vector illustration
Regulatory
FDA Delays Continue as Regulator Misses Review Date for GSK’s Nucala
The missed PDUFA adds to a string of delays at the FDA in recent weeks, including at least two other missed target action dates.
May 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative photo collage of funny young guy falling down shaming finger directing him stop corporate bullying isolated on pink background.
Layoffs
Rallybio Downsizes by 40% After Dropping Lead Asset
The company discontinued development last month of its most mature asset, RLYB212, following disappointing mid-stage pharmacokinetic findings in a rare bleeding disorder.
May 9, 2025
 · 
2 min read
 · 
Tristan Manalac
illustration of the ship in the storm, gigantic waves
Special edition
Deep Dive: Biopharma In Turmoil As Peter Marks Forced Out of FDA
Peter Marks, the venerable head of the FDA’s Center for Biologics Evaluation and Research, has been forced out. In this special edition of BioPharm Executive, BioSpace takes a deep dive into the instability of the HHS.
May 9, 2025
 · 
2 min read
 · 
Annalee Armstrong
Job Trends
2025 Q1 Job Market Report: Quarterly Job Postings Live Declined as Applications Spiked
Year-over-year BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the first quarter of 2025.
May 8, 2025
 · 
3 min read
 · 
Angela Gabriel
Pictured: Novavax/Getty Images, STR/NurPhoto
Earnings
Novavax Sales Jump 600% YoY as COVID-19 Vaccine Still in Limbo at FDA
After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its COVID-19 shot, CEO John Jacobs said on the company’s Q1 earnings call: “When we have it, we’ll have it. Until then, we don’t have it.”
May 8, 2025
 · 
3 min read
 · 
Heather McKenzie
Contemporary art collage. Businessman standing under heavy pressure. Working conditions. Concept of struggle, failure, success, competition, motivation, concentration, crisis, fear Copy space for ad
Cell therapy
Vor Bio Looks for Exit in Challenging Funding Environment; Lays Off 95% of Staff
The cell engineering company, co-founded by oncologist and writer Siddhartha Mukherjee, does not see a path forward for its pipeline of early-stage cell therapies for two different types of cancer.
May 8, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Illustration showing businessman avoiding potholes on way to goal
Job Trends
Job Market Woes: More Funding, Stability Needed for Turnaround
The biopharma job market likely won’t turn around until 2026, according to two industry experts. Both cited a need for more investment and noted the impact of uncertainty on the industry.
May 8, 2025
 · 
5 min read
 · 
Angela Gabriel
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS